I-Mab (IMAB) Stock Forecast, Price Target & Predictions
IMAB Stock Forecast
I-Mab stock forecast is as follows: a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
IMAB Analyst Ratings
According to 2 Wall Street analysts, I-Mab's rating consensus is 'Buy'. The analyst rating breakdown for IMAB stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 16, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Mar 18, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 17, 2022 | Needham | Buy | Buy | Hold |
| Jun 07, 2022 | Piper Sandler | Overweight | Overweight | Hold |
I-Mab's last stock rating was published by Piper Sandler on Sep 16, 2024. The company gave IMAB a "Overweight" rating, the same as its previous rate.
I-Mab Financial Forecast
I-Mab Revenue Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | $10.71M | $10.71M | - | $49.99M | $549.94M | $239.97M | $957.27M | $957.27M | - | $5.45M | $14.17M |
| High Forecast | - | - | $10.71M | $10.71M | - | $49.99M | $549.94M | $239.97M | $957.27M | $957.27M | - | $5.45M | $14.17M |
| Low Forecast | - | - | $10.71M | $10.71M | - | $49.99M | $549.94M | $239.97M | $957.27M | $957.27M | - | $5.45M | $14.17M |
| # Analysts | - | - | 1 | 1 | - | 1 | 1 | 1 | 1 | 1 | - | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
I-Mab's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. IMAB's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
I-Mab EBITDA Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | 1 | 1 | - | 1 | 1 | 1 | 1 | 1 | - | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | $-4.05M | $-4.05M | - | $-18.91M | $-207.97M | $-90.75M | $-362.02M | $-362.02M | - | $-2.06M | $-5.36M |
| High Forecast | - | - | $-4.05M | $-4.05M | - | $-18.91M | $-207.97M | $-90.75M | $-362.02M | $-362.02M | - | $-2.06M | $-5.36M |
| Low Forecast | - | - | $-4.05M | $-4.05M | - | $-18.91M | $-207.97M | $-90.75M | $-362.02M | $-362.02M | - | $-2.06M | $-5.36M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict IMAB's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than I-Mab's previous annual EBITDA (undefined) of $NaN.
I-Mab Net Income Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | 1 | 1 | - | 1 | 1 | 1 | 1 | 1 | - | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-86.70M | $-86.70M | - | - | $-398.75M | $-405.20M | $144.50M | $-384.32M | $714.02M | $714.02M | $-272.33M | $-180.55M | $-481.60M |
| High Forecast | $-86.70M | $-86.70M | - | - | $-398.75M | $-405.20M | $144.50M | $-384.32M | $714.02M | $714.02M | $-272.33M | $-180.55M | $-481.60M |
| Low Forecast | $-86.70M | $-86.70M | - | - | $-398.75M | $-405.20M | $144.50M | $-384.32M | $714.02M | $714.02M | $-272.33M | $-180.55M | $-481.60M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
I-Mab's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IMAB's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
I-Mab SG&A Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | 1 | 1 | - | 1 | 1 | 1 | 1 | 1 | - | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | $96.44M | $96.44M | - | $450.03M | $4.95B | $2.16B | $8.62B | $8.62B | - | $49.06M | $127.54M |
| High Forecast | - | - | $96.44M | $96.44M | - | $450.03M | $4.95B | $2.16B | $8.62B | $8.62B | - | $49.06M | $127.54M |
| Low Forecast | - | - | $96.44M | $96.44M | - | $450.03M | $4.95B | $2.16B | $8.62B | $8.62B | - | $49.06M | $127.54M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
I-Mab's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to IMAB last annual SG&A of $NaN (undefined).
I-Mab EPS Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | 1 | 1 | - | 1 | 1 | 1 | 1 | 1 | - | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-1.07 | $-1.07 | - | - | $-4.93 | $-5.01 | $1.79 | $-4.75 | $8.82 | $8.82 | $-3.36 | $-2.23 | $-5.95 |
| High Forecast | $-1.07 | $-1.07 | - | - | $-4.93 | $-5.01 | $1.79 | $-4.75 | $8.82 | $8.82 | $-3.36 | $-2.23 | $-5.95 |
| Low Forecast | $-1.07 | $-1.07 | - | - | $-4.93 | $-5.01 | $1.79 | $-4.75 | $8.82 | $8.82 | $-3.36 | $-2.23 | $-5.95 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, I-Mab's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IMAB previous annual EPS of $NaN (undefined).
I-Mab Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IMAB | I-Mab | $1.09 | $35.00 | 3111.01% | Buy |
| STTK | Shattuck Labs | $1.16 | $12.00 | 934.48% | Hold |
| LYEL | Lyell Immunopharma | $1.27 | $6.67 | 425.20% | Hold |
| APLS | Apellis Pharmaceuticals | $28.56 | $76.13 | 166.56% | Buy |
| ERAS | Erasca | $2.87 | $7.00 | 143.90% | Buy |
| FHTX | Foghorn Therapeutics | $8.24 | $16.33 | 98.18% | Buy |
| CGEM | Cullinan Oncology | $15.92 | $31.50 | 97.86% | Buy |
| DSGN | Design Therapeutics | $5.32 | $9.67 | 81.77% | Buy |
| ASND | Ascendis Pharma | $125.77 | $190.21 | 51.24% | Buy |
| IMVT | Immunovant | $29.42 | $42.83 | 45.58% | Buy |
| AKRO | Akero Therapeutics | $32.05 | $46.00 | 43.53% | Buy |
| NRIX | Nurix Therapeutics | $25.04 | $32.20 | 28.59% | Buy |
| BGNE | BeiGene | $207.25 | $255.80 | 23.43% | Buy |
| BPMC | Blueprint Medicines | $91.88 | $109.71 | 19.41% | Buy |
| KRYS | Krystal Biotech | $170.85 | $191.00 | 11.79% | Buy |
| KYMR | Kymera Therapeutics | $47.07 | $51.50 | 9.41% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $55.87 | $58.57 | 4.83% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
IMAB Forecast FAQ
Is I-Mab a good buy?
Yes, according to 2 Wall Street analysts, I-Mab (IMAB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of IMAB's total ratings.
What are I-Mab's analysts' financial forecasts?
I-Mab's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $962.72M (high $962.72M, low $962.72M), average EBITDA is $-364M (high $-364M, low $-364M), average net income is $261.14M (high $261.14M, low $261.14M), average SG&A $8.67B (high $8.67B, low $8.67B), and average EPS is $3.23 (high $3.23, low $3.23). IMAB's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $71.42M (high $71.42M, low $71.42M), average EBITDA is $-27.01M (high $-27.01M, low $-27.01M), average net income is $-804M (high $-804M, low $-804M), average SG&A $642.91M (high $642.91M, low $642.91M), and average EPS is $-9.934 (high $-9.934, low $-9.934).